FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904103135> ?p ?o ?g. }

• W2904103135 endingPage "464" @default.
• W2904103135 startingPage "459" @default.
• W2904103135 abstract "Patient-reported outcomes (PROs) are commonly included in submissions to the United States Food and Drug Administration (FDA). Open-label designs are frequent in cancer trials. Between-arm differences in PRO missingness may affect results. We sought to compare PRO completion rates between study arms in randomized open-label and double-blind cancer trials. Randomized, controlled trials for oncology and malignant hematology products submitted to the FDA in fiscal years 2007–2017 were identified using internal FDA databases. Applicant study reports were reviewed to assess PRO use and reporting of completion rates. Completion rates were collected for each PRO and compared between arms. Results were summarized using descriptive statistics. Ninety-six trials for anticancer products from 2007 to 2017 contained PROs. Fifty-one (53.1%) were randomized, controlled trials with useable information on PRO completion. The median completion rate for investigational arms was 89.7% (range = 33.7–100.0%) and 88.2% (range = 11.0–100.0%) for control arms. At six months, seven double-blind trials had gaps of at least 10% in at least one PRO between arms; in four trials, these gaps favored the control arm (median difference = 11.5%, range = 10.0–17.0%). For open-label trials, four trials had such gaps, all of which favored the investigational arm (median difference = 28.5%, range = 10.0–69.0%). Among trials that provided interpretable PRO completion information, completion rates were high. Most trials had comparable completion rates between arms. However, when large between-arm completion rate differences existed, differences favoring the experimental arm were more common in open-label trials compared with double-blind trials. Procedures must be put in place to improve reporting of PRO completion and reduce missingness, particularly in open-label trials." @default.
• W2904103135 created "2018-12-22" @default.
• W2904103135 creator A5010221662 @default.
• W2904103135 creator A5014736110 @default.
• W2904103135 creator A5019635241 @default.
• W2904103135 creator A5046986750 @default.
• W2904103135 creator A5056460836 @default.
• W2904103135 date "2018-12-17" @default.
• W2904103135 modified "2023-09-30" @default.
• W2904103135 title "Blinding and Patient-Reported Outcome Completion Rates in US Food and Drug Administration Cancer Trial Submissions, 2007–2017" @default.
• W2904103135 cites W1989742071 @default.
• W2904103135 cites W2006175454 @default.
• W2904103135 cites W2016794739 @default.
• W2904103135 cites W2070847622 @default.
• W2904103135 cites W2081810479 @default.
• W2904103135 cites W2095124683 @default.
• W2904103135 cites W2102355184 @default.
• W2904103135 cites W2123874025 @default.
• W2904103135 cites W2339162560 @default.
• W2904103135 cites W2523715715 @default.
• W2904103135 cites W2529787110 @default.
• W2904103135 cites W2531933671 @default.
• W2904103135 cites W2751041540 @default.
• W2904103135 cites W2782908833 @default.
• W2904103135 cites W2793539832 @default.
• W2904103135 cites W4242114665 @default.
• W2904103135 doi "https://doi.org/10.1093/jnci/djy181" @default.
• W2904103135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30561711" @default.
• W2904103135 hasPublicationYear "2018" @default.
• W2904103135 type Work @default.
• W2904103135 sameAs 2904103135 @default.
• W2904103135 citedByCount "26" @default.
• W2904103135 countsByYear W29041031352018 @default.
• W2904103135 countsByYear W29041031352019 @default.
• W2904103135 countsByYear W29041031352020 @default.
• W2904103135 countsByYear W29041031352021 @default.
• W2904103135 countsByYear W29041031352022 @default.
• W2904103135 countsByYear W29041031352023 @default.
• W2904103135 crossrefType "journal-article" @default.
• W2904103135 hasAuthorship W2904103135A5010221662 @default.
• W2904103135 hasAuthorship W2904103135A5014736110 @default.
• W2904103135 hasAuthorship W2904103135A5019635241 @default.
• W2904103135 hasAuthorship W2904103135A5046986750 @default.
• W2904103135 hasAuthorship W2904103135A5056460836 @default.
• W2904103135 hasConcept C121608353 @default.
• W2904103135 hasConcept C126322002 @default.
• W2904103135 hasConcept C141071460 @default.
• W2904103135 hasConcept C168563851 @default.
• W2904103135 hasConcept C204243189 @default.
• W2904103135 hasConcept C2771230 @default.
• W2904103135 hasConcept C3018890749 @default.
• W2904103135 hasConcept C535046627 @default.
• W2904103135 hasConcept C71924100 @default.
• W2904103135 hasConcept C98274493 @default.
• W2904103135 hasConceptScore W2904103135C121608353 @default.
• W2904103135 hasConceptScore W2904103135C126322002 @default.
• W2904103135 hasConceptScore W2904103135C141071460 @default.
• W2904103135 hasConceptScore W2904103135C168563851 @default.
• W2904103135 hasConceptScore W2904103135C204243189 @default.
• W2904103135 hasConceptScore W2904103135C2771230 @default.
• W2904103135 hasConceptScore W2904103135C3018890749 @default.
• W2904103135 hasConceptScore W2904103135C535046627 @default.
• W2904103135 hasConceptScore W2904103135C71924100 @default.
• W2904103135 hasConceptScore W2904103135C98274493 @default.
• W2904103135 hasIssue "5" @default.
• W2904103135 hasLocation W29041031351 @default.
• W2904103135 hasLocation W29041031352 @default.
• W2904103135 hasOpenAccess W2904103135 @default.
• W2904103135 hasPrimaryLocation W29041031351 @default.
• W2904103135 hasRelatedWork W1967744186 @default.
• W2904103135 hasRelatedWork W1999967090 @default.
• W2904103135 hasRelatedWork W2019275370 @default.
• W2904103135 hasRelatedWork W2068364322 @default.
• W2904103135 hasRelatedWork W2076362722 @default.
• W2904103135 hasRelatedWork W2082673550 @default.
• W2904103135 hasRelatedWork W2089908284 @default.
• W2904103135 hasRelatedWork W2894665084 @default.
• W2904103135 hasRelatedWork W3207429845 @default.
• W2904103135 hasRelatedWork W4377151426 @default.
• W2904103135 hasVolume "111" @default.
• W2904103135 isParatext "false" @default.
• W2904103135 isRetracted "false" @default.
• W2904103135 magId "2904103135" @default.
• W2904103135 workType "article" @default.